GGPS1 mutation and atypical femoral fractures with bisphosphonates.
Atypical femoral fractures have been associated with long-term bisphosphonate treatment.1,2 However, the underlying mechanisms remain obscure. We studied three sisters who had atypical femoral fractures after receiving various oral bisphosphonates for 6 years. Two of the sisters had a single fractur...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Massachusetts Medical Society
2017
|
| _version_ | 1826257218507374592 |
|---|---|
| author | Roca-Ayats, N Balcells, S Garcia-Giralt, N Falcó-Mascaró, M Martínez-Gil, N Abril, J Urreizti, R Dopazo, J Quesada-Gómez, J Nogués, X Mellibovsky, L Prieto-Alhambra, D Dunford, J Javaid, M Russell, R Grinberg, D Díez-Pérez, A |
| author_facet | Roca-Ayats, N Balcells, S Garcia-Giralt, N Falcó-Mascaró, M Martínez-Gil, N Abril, J Urreizti, R Dopazo, J Quesada-Gómez, J Nogués, X Mellibovsky, L Prieto-Alhambra, D Dunford, J Javaid, M Russell, R Grinberg, D Díez-Pérez, A |
| author_sort | Roca-Ayats, N |
| collection | OXFORD |
| description | Atypical femoral fractures have been associated with long-term bisphosphonate treatment.1,2 However, the underlying mechanisms remain obscure. We studied three sisters who had atypical femoral fractures after receiving various oral bisphosphonates for 6 years. Two of the sisters had a single fracture (at the ages of 64 and 73 years), and one had bilateral fractures (one at the age of 60 years and the other at the age of 61 years). Given the low incidence of atypical femoral fractures in the general population (5.9 per 10,000 person-years),3 we hypothesized that these sisters might have an underlying genetic background that contributed to these fractures. |
| first_indexed | 2024-03-06T18:14:39Z |
| format | Journal article |
| id | oxford-uuid:04337fcf-e3ab-44c9-941a-4801f1a66d8f |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T18:14:39Z |
| publishDate | 2017 |
| publisher | Massachusetts Medical Society |
| record_format | dspace |
| spelling | oxford-uuid:04337fcf-e3ab-44c9-941a-4801f1a66d8f2022-03-26T08:50:36ZGGPS1 mutation and atypical femoral fractures with bisphosphonates.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:04337fcf-e3ab-44c9-941a-4801f1a66d8fEnglishSymplectic Elements at OxfordMassachusetts Medical Society2017Roca-Ayats, NBalcells, SGarcia-Giralt, NFalcó-Mascaró, MMartínez-Gil, NAbril, JUrreizti, RDopazo, JQuesada-Gómez, JNogués, XMellibovsky, LPrieto-Alhambra, DDunford, JJavaid, MRussell, RGrinberg, DDíez-Pérez, AAtypical femoral fractures have been associated with long-term bisphosphonate treatment.1,2 However, the underlying mechanisms remain obscure. We studied three sisters who had atypical femoral fractures after receiving various oral bisphosphonates for 6 years. Two of the sisters had a single fracture (at the ages of 64 and 73 years), and one had bilateral fractures (one at the age of 60 years and the other at the age of 61 years). Given the low incidence of atypical femoral fractures in the general population (5.9 per 10,000 person-years),3 we hypothesized that these sisters might have an underlying genetic background that contributed to these fractures. |
| spellingShingle | Roca-Ayats, N Balcells, S Garcia-Giralt, N Falcó-Mascaró, M Martínez-Gil, N Abril, J Urreizti, R Dopazo, J Quesada-Gómez, J Nogués, X Mellibovsky, L Prieto-Alhambra, D Dunford, J Javaid, M Russell, R Grinberg, D Díez-Pérez, A GGPS1 mutation and atypical femoral fractures with bisphosphonates. |
| title | GGPS1 mutation and atypical femoral fractures with bisphosphonates. |
| title_full | GGPS1 mutation and atypical femoral fractures with bisphosphonates. |
| title_fullStr | GGPS1 mutation and atypical femoral fractures with bisphosphonates. |
| title_full_unstemmed | GGPS1 mutation and atypical femoral fractures with bisphosphonates. |
| title_short | GGPS1 mutation and atypical femoral fractures with bisphosphonates. |
| title_sort | ggps1 mutation and atypical femoral fractures with bisphosphonates |
| work_keys_str_mv | AT rocaayatsn ggps1mutationandatypicalfemoralfractureswithbisphosphonates AT balcellss ggps1mutationandatypicalfemoralfractureswithbisphosphonates AT garciagiraltn ggps1mutationandatypicalfemoralfractureswithbisphosphonates AT falcomascarom ggps1mutationandatypicalfemoralfractureswithbisphosphonates AT martinezgiln ggps1mutationandatypicalfemoralfractureswithbisphosphonates AT abrilj ggps1mutationandatypicalfemoralfractureswithbisphosphonates AT urreiztir ggps1mutationandatypicalfemoralfractureswithbisphosphonates AT dopazoj ggps1mutationandatypicalfemoralfractureswithbisphosphonates AT quesadagomezj ggps1mutationandatypicalfemoralfractureswithbisphosphonates AT noguesx ggps1mutationandatypicalfemoralfractureswithbisphosphonates AT mellibovskyl ggps1mutationandatypicalfemoralfractureswithbisphosphonates AT prietoalhambrad ggps1mutationandatypicalfemoralfractureswithbisphosphonates AT dunfordj ggps1mutationandatypicalfemoralfractureswithbisphosphonates AT javaidm ggps1mutationandatypicalfemoralfractureswithbisphosphonates AT russellr ggps1mutationandatypicalfemoralfractureswithbisphosphonates AT grinbergd ggps1mutationandatypicalfemoralfractureswithbisphosphonates AT diezpereza ggps1mutationandatypicalfemoralfractureswithbisphosphonates |